Skip to NavigationSkip to content

Otsuka to take over Astellas’ Cefixime business

Published on 07/06/19 at 09:46am

Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime.

The agreement gives Otsuka the right to sell Cefixime and supply the active pharmaceutical ingredient (API) to overseas licensees.

The move comes as part of an effort from Otsuka to strengthen their grounding in the API business.

Astellas’ Cefixime is a third generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria. The antibiotic is prescribed around the world.

Otsuka said they intend to further strengthen their business through new technologies as they take advantage of key technologies.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches